石杉碱甲治疗轻度认知障碍患者有效性与安全性的系统评价与Meta分析

Efficacy and safety of huperzine A in treating patients with mild cognitive impairment: a systematic review and Meta-analysis

该文评价石杉碱甲治疗轻度认知障碍患者的有效性与安全性。通过计算机检索中国生物医学文献数据库(CBM)、中国知网(CNKI)、万方医学数据库、维普数据库、PubMed、Cochrane Library、EMbase等数据库,纳入石杉碱甲治疗轻度认知障碍的随机对照试验,对纳入研究的方法学质量进行评价,利用RevMan 5.3软件进行统计分析。结果共纳入9项随机对照研究。Meta分析结果显示,对轻度认知障碍患者,石杉碱甲在提高韦氏记忆商(MQ)、简易智能精神状态量表评分(MMSE)方面明显优于安慰剂。石杉碱甲口服片剂与胶囊剂在MQ,MMSE提高方面无统计学差异。结果表明石杉碱甲在提高轻度认知障碍患者记忆商数、简易智能精神状态量表评分方面优于安慰剂,且不良反应发生率低,具有较好的临床安全性,可供临床参考使用。鉴于纳入研究的质量偏低,需要更多高质量临床研究进一步证实。

To evaluate the efficacy and safety of huperzine in treating patients with mild cognitive impairment. The randomized controlled trials(RCT) were retrieved from EMbase, Cochrane Library, PubMed, CNKI, Wanfang and VIP. The methodology quality of the included studies was evaluated, and a Meta-analysis was performed using RevMan 5.3 software. A total of nine RCTs were included. The Meta-analysis results showed that compared with placebo, Huperzine significantly increased the scores of memory quotient(MQ) and mini-mental state examination(MMSE). However, there was no statistical difference between oral tablet and capsule. Compared with placebo, huperzine A was superior in the scores of MQ and MMSE. Huperzine is safe with mild side effects. Due to the low quality of original studies, more high-quality studies are needed to verify its efficacy.